Oral Treprostinil in Subjects With Pulmonary Hypertension Associated With Pulmonary Fibrosis

PHASE2WithdrawnINTERVENTIONAL
0
Timeline

Start Date

February 29, 2016

Primary Completion Date

April 30, 2018

Study Completion Date

July 31, 2018

Conditions
Pulmonary HypertensionPulmonary Fibrosis
Interventions
DRUG

Oral treprostinil

Oral treprostinil will be administered as TID dosing for up to 16 Weeks.

Trial Locations (7)

15213

CLC Pulmonary Hypertension Clinic Division of Pulmonary, Allergy and Critical Care Medicine UPMC, Pittsburgh

21205

Johns Hopkins University, Baltiomore

30322

Emory University Hospital, Atlanta

85006

Banner University Medical Center Phoenix Advanced Lung Disease, Phoenix

90024

University of California, Los Angeles - Pulmonary Division, Los Angeles

95817

University of California - Davis Medical Group, Sacramento

97239

Oregon Health and Science University, Portland

Sponsors
All Listed Sponsors
lead

United Therapeutics

INDUSTRY

NCT02603068 - Oral Treprostinil in Subjects With Pulmonary Hypertension Associated With Pulmonary Fibrosis | Biotech Hunter | Biotech Hunter